Oral Semaglutide Demonstrates Greater Weight Loss vs Orforglipron in Indirect Comparison

New data from a population-adjusted indirect treatment comparison suggest that oral semaglutide (Wegovy in a pill; Novo Nordisk) may provide greater weight loss and improved tolerability compared with orforglipron (Foundayo; Eli Lilly and Company), offering important insights for clinicians navigating an expanding class of oral glucagon-like peptide-1 (GLP-1) receptor agonists.¹

The findings, derived from the ORION analysis, compared oral semaglutide 25 mg with orforglipron 36 mg using data from separate phase 3 trials, including OASIS 4 (NCT05564117) and ATTAIN-1 (NCT05869903). As oral GLP-1 therapies gain traction in weight management, these data arrive at a critical time for pharmacists and clinicians evaluating treatment selection based on efficacy, safety, and patient preference.^1-3

Greater Weight Loss Observed With Oral Semaglutide

Results from the analysis showed that oral semaglutide was associated with significantly greater weight loss compared with orforglipron. The mean difference in body weight reduction was approximately 3 percentage points in favor of oral semaglutide, regardless of whether patients stayed on treatment (95% CI, –5.9 to –0.4) and if all patients stayed on treatment (95% CI, –5.8 to –0.3).¹

These findings build on prior evidence demonstrating robust weight loss with oral semaglutide in the OASIS clinical program, where patients achieved mean reductions of up to 16.6% of baseline body weight. Specifically, in OASIS 4, there was an estimated mean change in body weight of 13.6% with oral semaglutide from baseline to week 64.^4,5

For pharmacists, these differences may be clinically relevant when counseling patients who have weight-loss goals tied to comorbidity reduction, including improvements in cardiovascular risk or glycemic control. Even modest differences in percentage weight loss can influence long-term outcomes, particularly in patients with obesity-related conditions.

Tolerability Differences May Influence Adherence

Beyond efficacy, the analysis identified notable differences in tolerability. Patients receiving orforglipron had approximately 4 times higher odds of discontinuation due to any adverse event (OR, 4.1; 95% CI, 1.3-13.0) and nearly 14 times higher odds of discontinuation due to gastrointestinal (GI) adverse events (OR, 13.9; 95% CI, 2.0-96.0) compared with those receiving oral semaglutide.¹

GI adverse effects remain a key consideration across the GLP-1 class, often affecting adherence and persistence. For pharmacists, proactive counseling on expected adverse effects, such as nausea, vomiting, and diarrhea, can play a central role in optimizing treatment continuation and outcomes.

These findings also align with broader observations in the class, where tolerability profiles can meaningfully differentiate therapies despite similar mechanisms of action.⁴

Contextualizing Findings in a Competitive Landscape

The comparison reflects increasing competition between oral GLP-1 therapies, particularly following the recent FDA approval of orforglipron for chronic weight management. As newer agents enter the market, clinicians must interpret cross-trial and indirect comparisons cautiously, given differences in study design, patient populations, and dosing strategies.^1,6

Earlier head-to-head data in type 2 diabetes populations have shown contrasting results, with orforglipron demonstrating greater reductions in hemoglobin A_1c and body weight compared with lower-dose oral semaglutide formulations. This highlights the importance of dose selection and indication when evaluating comparative efficacy.⁷

For pharmacists, these nuances reinforce the need to individualize therapy selection based on patient-specific factors, including treatment goals, comorbidities, tolerability, and access considerations.

Patient Preference and Practical Considerations for Pharmacists

In addition to clinical outcomes, patient preference may influence real-world utilization. Survey data released by Novo Nordisk from over 800 respondents suggest that most patients favored a treatment profile like oral semaglutide over one resembling orforglipron. Furthermore, most respondents said that taking oral semaglutide—which requires taking the treatment on an empty stomach and waiting 30 minutes before eating—would not disrupt their lives.¹

As oral therapies continue to expand access to GLP-1–based treatment, pharmacists are uniquely positioned to guide shared decision-making. Discussions about dosing convenience, adverse effect management, and expectations for weight loss can help align therapy with patient priorities.

Pharmacists will play an increasingly important role in translating emerging evidence into practice as the GLP-1 drug class continues to proliferate. Indirect comparisons such as ORION provide valuable—but not definitive—insights that can inform therapeutic decision-making. Ultimately, optimizing outcomes will depend on balancing efficacy with tolerability and adherence. For pharmacists, this means not only understanding comparative data but also actively engaging patients in education, monitoring, and ongoing support throughout treatment.

REFERENCES

1. Wegovy pill demonstrated greater weight loss than orforglipron and lower odds of stopping medication due to side effects in a population-adjusted indirect comparison. News release. Novo Nordisk. Released April 2, 2026. Accessed April 2, 2026. https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916526

2. Research study looking at how well semaglutide tablets taken once daily work in people who have a body weight above the healthy range (OASIS 4). Novo Nordisk. Updated February 25, 2026. Accessed April 2, 2026. https://clinicaltrials.gov/study/NCT05564117

3. A study of orforglipron (LY3502970) in adult participants with obesity or overweight with weight-related comorbidities (ATTAIN-1). Eli Lilly and Company. Updated November 5, 2025. Accessed April 2, 2026. https://clinicaltrials.gov/study/NCT05869903

4. Novo Nordisk A/S: Wegovy (semaglutide) pill approved in the US as first oral GLP-1 for weight management. News release. Novo Nordisk. December 22, 2025. Accessed April 2, 2026. https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916472

5. Valletti D. FDA approves first oral GLP-1 for weight management. Pharmacy Times. December 23, 2025. Accessed April 2, 2026. https://www.pharmacytimes.com/view/fda-approves-first-oral-glp-1-for-weight-management

6. McGovern G. FDA approves orforglipron, first GLP-1 pill without time, food, or water restrictions. Pharmacy Times. April 1, 2026. Accessed April 2, 2026. https://www.pharmacytimes.com/view/fda-approves-orforglipron-first-glp-1-pill-without-time-food-or-water-restrictions

7. Halpern L. Orforglipron outperforms oral semaglutide in head-to-head T2D trial. Pharmacy Times. February 26, 2026. Accessed April 2, 2026. https://www.pharmacytimes.com/view/orforglipron-outperforms-oral-semaglutide-in-head-to-head-t2d-trial